- Home
- TEI vs SMTI Comparison
TEI vs SMTI Comparison
Compare TEI & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- SMTI
- Stock Information
- Founded
- TEI 1993
- SMTI 1982
- Country
- TEI United States
- SMTI United States
- Employees
- TEI N/A
- SMTI N/A
- Industry
- TEI Finance Companies
- SMTI Medical/Dental Instruments
- Sector
- TEI Finance
- SMTI Health Care
- Exchange
- TEI Nasdaq
- SMTI Nasdaq
- Market Cap
- TEI 242.3M
- SMTI 288.2M
- IPO Year
- TEI N/A
- SMTI N/A
- Fundamental
- Price
- TEI $5.22
- SMTI $32.64
- Analyst Decision
- TEI
- SMTI Strong Buy
- Analyst Count
- TEI 0
- SMTI 2
- Target Price
- TEI N/A
- SMTI $47.00
- AVG Volume (30 Days)
- TEI 142.4K
- SMTI 28.9K
- Earning Date
- TEI 01-01-0001
- SMTI 11-12-2024
- Dividend Yield
- TEI 10.51%
- SMTI N/A
- EPS Growth
- TEI N/A
- SMTI N/A
- EPS
- TEI N/A
- SMTI N/A
- Revenue
- TEI N/A
- SMTI $78,056,873.00
- Revenue This Year
- TEI N/A
- SMTI $30.48
- Revenue Next Year
- TEI N/A
- SMTI $24.07
- P/E Ratio
- TEI N/A
- SMTI N/A
- Revenue Growth
- TEI N/A
- SMTI 24.66
- 52 Week Low
- TEI $4.35
- SMTI $26.00
- 52 Week High
- TEI $5.39
- SMTI $40.75
- Technical
- Relative Strength Index (RSI)
- TEI 48.67
- SMTI 43.29
- Support Level
- TEI $5.08
- SMTI $31.99
- Resistance Level
- TEI $5.29
- SMTI $33.59
- Average True Range (ATR)
- TEI 0.07
- SMTI 1.22
- MACD
- TEI 0.02
- SMTI 0.01
- Stochastic Oscillator
- TEI 66.67
- SMTI 35.69
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.
About SMTI Sanara MedTech Inc.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.